Treatment of patients with advanced gastrointestinal stromal tumor of small bowel: Implications of imatinib mesylate

Figure 1 Sequential CT scans obtained in the same patient at base line (before treatment, upper row), middle row (2 year after Glivec treatment), and lower row (50 mo after Blivec treatment). The CT scans revealed partial response of the tumor at the same level.

Figure 2 Sequential PET scans obtained in the same patient at base line (before treatment, upper row), and 1 mo after Glivec treatment (lower row). The PET scans revealed partial response of the tumor at the same level.

Figure 3 Mutation spectrum of the 8 small bowel GIST patients.

Figure 4 Post-recurrence survival rate of 55 small bowel GIST patients treated with and without Glivec.

Figure 5 Overall survival rate of 55 small bowel GIST patients treated with or without Glivec.